Insight Molecular Diagnostics (NASDAQ: IMDX) boosts CEO and CFO base pay

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.

false 0001642380 0001642380 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 16, 2025

Insight Molecular Diagnostics Inc.

(Exact name of registrant as specified in its charter)

California		1-37648		27-1041563
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

(615) 255-8880

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		IMDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 16, 2025, the Board of Directors (the “Board”) of Insight Molecular Diagnostics Inc. (the “Company”) and the Compensation Committee of the Board approved increases to the annual base salaries of (i) Joshua Riggs, the Company’s President and Chief Executive Officer, from $420,000 to $520,000 and (ii) Andrea James, the Company’s Chief Financial Officer, from $341,250 to $441,250. Each of the salary increases is effective as of September 15, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INSIGHT MOLECULAR DIAGNOSTICS INC.
Date: September 19, 2025	By:	/s/ Peter Hong
		Peter Hong
		Vice President, General Counsel

FAQ

What executive compensation changes did IMDX disclose in this 8-K filing?

Insight Molecular Diagnostics Inc. disclosed that its Board and Compensation Committee approved base salary increases for its President and CEO, Joshua Riggs, and its CFO, Andrea James, effective September 15, 2025.

How much did Insight Molecular Diagnostics increase the CEO’s salary?

The annual base salary of CEO Joshua Riggs increased from $420,000 to $520,000, reflecting a higher level of cash compensation for his role.

What is the new base salary for Insight Molecular Diagnostics’ CFO?

The annual base salary of CFO Andrea James increased from $341,250 to $441,250, as approved by the Board and Compensation Committee.

When did the executive salary increases at IMDX become effective?

The salary increases for both the CEO and CFO became effective on September 15, 2025, as stated in the filing.

Did Insight Molecular Diagnostics report any director departures or new appointments?

The filing is presented under an item covering departures or appointments of directors and officers and compensatory arrangements, but the specific disclosure in this document focuses on executive salary increases for the CEO and CFO.

Which stock exchange lists Insight Molecular Diagnostics common stock?

Insight Molecular Diagnostics Inc.’s common stock, trading under the symbol IMDX, is listed on The Nasdaq Stock Market LLC.